Gleason grading system
The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance. Cancers with a higher Gleason score are more aggressive and have a worse prognosis.
Specimens and processing
Most often, a urologist or radiologist will remove a cylindrical sample (biopsy) of prostate tissue through the rectum, using hollow needles, and biomedical scientists in a Histology laboratory prepare microscope slides for H&E staining and Immunohistochemistry for diagnosis by a pathologist. If the prostate is surgically removed, a pathologist will slice the prostate for a final examination.
A pathologist microscopically examines the biopsy specimen for certain "Gleason" patterns. These Gleason patterns are associated with the following features:
- Pattern 1 - The cancerous prostate closely resembles normal prostate tissue. The glands are small, well-formed, and closely packed. This corresponds to a well differentiated carcinoma.
- Pattern 2 - The tissue still has well-formed glands, but they are larger and have more tissue between them, implying that the stroma has increased. This also corresponds to a moderately differentiated carcinoma.
- Pattern 3 - The tissue still has recognizable glands, but the cells are darker. At high magnification, some of these cells have left the glands and are beginning to invade the surrounding tissue or having an infiltrative pattern. This corresponds to a moderately differentiated carcinoma.
- Pattern 4 - The tissue has few recognizable glands. Many cells are invading the surrounding tissue in neoplastic clumps. This corresponds to a poorly differentiated carcinoma.
- Pattern 5 - The tissue does not have any or only a few recognizable glands. There are often just sheets of cells throughout the surrounding tissue. This corresponds to an anaplastic carcinoma.
In the present form of the Gleason system, prostate cancer of Gleason patterns 1 and 2 are rarely seen. Gleason pattern 3 is by far the most common.
Primary, secondary and tertiary grades
A pathologist then assigns a grade to the observed patterns of the tumor specimen.
- Primary grade - assigned to the dominant pattern of the tumor (has to be greater than 50% of the total pattern seen).
- Secondary grade - assigned to the next-most frequent pattern (has to be less than 50%, but at least 5%, of the pattern of the total cancer observed).
- Tertiary grade - increasingly, pathologists provide details of the "tertiary" component. This is where there is a small component of a third (generally more aggressive) pattern.
Scores and prognoses
The pathologist then sums the pattern-number of the primary and secondary grades to obtain the final Gleason score. If only two patterns are seen, the first number of the score is that of the tumor's primary grade while the second number is that of the secondary grade, as described in the previous section. If three patterns are seen, the first number of the score would be the primary grade and the second number the pattern with the highest grade. For example, if the primary tumor grade was 2 and the secondary tumor grade was 3 but some cells were found to be grade 4, the Gleason score would be 2+4=6. This is a slight change from the pre-2005 Gleason system where the second number was the secondary grade (i.e., the grade of the second-most common cell line pattern).
Gleason scores range from 2 to 10, with 2 representing the most well-differentiated tumors and 10 the least-differentiated tumors. Gleason scores have often been categorized into groups that show similar biologic behavior: low-grade (well-differentiated), intermediate-grade, moderate to poorly differentiated or high-grade. More recently, an investigation of the Johns Hopkins Radical Prostatectomy Database (1982-2011) led to the proposed reporting of Gleason grades and prognostic grade groups as: Gleason score ≤ 6 (prognostic grade group I); Gleason score 3+4=7 (prognostic grade group II); Gleason score 4+3=7 (prognostic grade group III); Gleason score 4+4=8 (prognostic grade group IV); Gleason scores 9-10 (prognostic grade group V). Prostate cancers with a Gleason score ≤ 6 usually have rather good prognoses.
Gleason architectural pattern and Gleason grade are interchangeable terms.
The Gleason Grade/Score has two main points: 1: Based on architectural patterns, rather than cytological ones. The Gleason System separates architectural features into 1 of 5 histological patterns. These are in decreasing differentiation order but increasing in number: Pattern 1 is the most differentiated and pattern 5 is the least differentiated.
(with less differentiation in "cancer" typically being a worse prognosis. Differentiation is the degree in which the tissue, usually referring to the neoplasm, resembles the native tissue. So less resemblance is typically a worse prognosis.)
2: The second feature of Gleason grading is that the grade is not based on the highest (least differentiated) pattern within the tumor, instead it is a combination of the most often and second most often patterns seen. Gleason realized that prostatic carcinomas have multiple patterns and that the prognosis of prostatic carcinoma was split between the most prevalent and the second most prevalent neoplasm pattern. So using the Gleason system, the most prevalent and second most prevalent pattern, if at least 5% of the neoplasm, are added together equaling the overall Gleason score.
If for example the most prevalent pattern/grade is 2, and the second most prevalent is a 1, then the Gleason score is 2+1=3. If the neoplasm has only one pattern, the number of the pattern is doubled to obtain the score. For example a tumor is all pattern 1, the Gleason score would be 1+1=2. The most differentiated tumor will have, at highest, a Gleason score of 2 (1+1 being all of type 1 architecture it just gets doubled), while the worst differentiated neoplasm (not resembling the native prostate tissue at all) will have a score of 10 (5+5 also being all type 5 tissue). So a Gleason Score/Grade can only be between 2 and 10, there is no 0 or 1 by definition.
The main way to tell the difference between a normal prostate gland and neoplastic glands is that prostatic glands normally have two cell layers in the glands, in adenocarcinoma (adeno- being that it is glandular cancer, carcinoma- being that its ectoderm derived because only ectodermal tissue makes glands) the basal (bottom-usually cuboidal) cell layer is lost so that you only have one top layer of cellular tissue usually ranging from columnar- pseudostratified in appearance.
Using this system the most well-differentiated tumors have a Gleason score/grade of 2, and the least-differentiated tumors a score of 10. Range by definition is from 2-10, with architectural type being from 1-5 and always doubled or added together accordingly as described above. Gleason scores are often grouped based on similar behaviour: Grade 2-4 being well-differentiated neoplasm, Grade 5-6 intermediate-grade neoplasm, Grade 7 moderately - poorly differentiated grade neoplasm, Grade 8-10 high-grade neoplasm.
Gleason pattern 1 is the most well differentiated tumor pattern. It is a well defined nodule of single/separate, closely/densely packed, back-to-back gland pattern that does not invade into adjacent healthy prostatic tissue. The glands are round to oval shaped and proportionally large, comparing them to Gleason pattern 3 tumors, and are approximately equal in size and shape to one another.
Gleason 2 are fairly well circumscribed nodules of single, separate glands. However, the glands are looser in arrangement and not as uniform as in pattern 1. Minimal invasion by neoplastic glands into the surrounding healthy prostate tissue may be seen. Similar to Gleason 1, the glands are usually larger than those of Gleason 3 patterns, and are round to oval in shape. Thus the main difference between Gleason 1 and 2 is the density of packing of the glands seen and invasion is possible in Gleason 2, not in Gleason 1 by definition.
Gleason 3 is a clearly infiltrative neoplasm, with extension into adjacent healthy prostate tissue. The glands alternate in size and shape, and are often long/angular. They are usually small/micro-glandular in comparison to Gleason 1 or 2 grades. However, some may be medium to large in size. The small glands of Gleason 3, in comparison to the small and poorly defined glands of pattern 4, are distinct glandular units. Mentally you could draw a circle around each of the glandular units in Gleason 3.
Gleason pattern 4 glands are no longer single/separated glands like those seen in pattern 1-3. They look fused together, difficult to distinguish, with rare lumen formation vs Gleason 1-3 which usually all have open lumens (spaces) within the glands, or they can be cribriform-(resembling the cribriform plate/similar to a sieve. An item with many perforations). Fused glands are chains, nests, or groups of glands that are no longer entirely separated by stroma-(connective tissue that normally separates individual glands in this case). Fused glands contain occasional stroma giving the appearance of "partial" separation of the glands. Due to this partial separation, fused glands sometimes have a scalloped (think looking at a slice of bread with bite taken out of it) appearance at their edges.
Neoplasms have no glandular differentiation (thus not resembling normal prostate tissue at all). It is composed of sheets (groups of cells almost planar in appearance (like the top of a box), solid cords (group of cells in a rope like fashion running through other tissue/cell patterns seen), or individual cells. You should not see round glands with lumenal spaces that can be seen in the other types that resemble more the normal prostate gland appearance.
Gleason scores 2-4 are typically found in smaller tumors located in the transitional zone (around the urethra). These are typically found incidentally on surgery for benign prostatic hypertrophy (Note: not a precursor lesion for prostatic carcinoma).
The majority of treatable/treated cancers are of Gleason scores 5 - 7 and are detected due to biopsy after abnormal digital rectal exam or prostate specific antigen evaluation. The cancer is typically located in the peripheral zone usually the posterior portion, explaining the rationale of performing the digital rectal exam.
Tumors with Gleason scores 8-10 tend to be advanced neoplasms that are unlikely to be cured. Although some evidence suggests that prostate cancers will become more aggressive over time, most often Gleason scores remain stable for a few years.
The Gleason scores then become part of the TNM or Whitmore-Jewett Prostate cancer staging system to provide prognosis.
The scoring system is named after Donald Gleason, a pathologist at the Minneapolis Veterans Affairs Hospital, who developed it with colleagues at that facility in the 1960s. In 2005, the Gleason system was altered by the International Society of Urological Pathology. The criteria were refined and the attribution of certain patterns changed. It has been shown that this 'modified Gleason score' has higher performance than the original one, and is currently assumed standard in urological pathology. In this form, it remains an important tool.
However, problematic aspects of the original Gleason grading system still characterize the 2005 revision. The predominant lowest score assigned is Gleason 3+3 = 6. Patients who are told their Gleason score is 6 out of 10 may interpret that they have a more aggressive intermediate cancer and experience greater anxiety. More importantly, some classification systems fail to clearly distinguish between Gleason 3+4 = 7 and Gleason 4+3 = 7, with the latter having a worse prognosis. Therefore, in 2014 an international multidisciplinary conference was convened to revise the 2005 system. A 5-point scale similar to those such as PI-RADS used with prostate MRI evaluations was proposed to denote prognostically distinct grades. The number 1 would indicate the lowest risk cancer while 5 would indicate the most aggressive disease. The system was tested and validated against 20,000 prostatectomy specimens and at least 16,000 biopsy samples. The majority of conference participants concurred on the superiority of the scale over the 2005 Gleason grading system, pointing to the likelihood that overtreatment could be avoided for patients whose cancer was assigned a 1. The World Health Organization’s 2016 edition of Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs has accepted the 2014 system, which can be used in conjunction with the 2005 Gleason system.
- "Male Genital Pathology". Retrieved 2009-05-13.
- Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29(9):1228-42.
- Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. Seventh ed: Elsevier Saunders; 2005.
- Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU International. 2013;111(5):753-760.
- Manage Account - Modern Medicine
- Gleason, D. F. (1977). "The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma". In Tannenbaum, M. Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger. pp. 171–198. ISBN 0-8121-0546-X.
- Brimo, Fadi; Montironi, Rodolfo; Egevad, Lars; Erbersdobler, Andreas; Lin, Daniel W.; Nelson, Joel B.; Rubin, Mark A.; van der Kwast, Theo; Amin, Mahul; Epstein, Jonathan I. (May 2013). "Contemporary Grading for Prostate Cancer: Implications for Patient Care". European Urology. 63 (5): 892–901. doi:10.1016/j.eururo.2012.10.015.
- "8 tell how they handle testing, anxiety of prostate cancer waiting". The Philadelphia Inquirer. Retrieved 31 March 2016.
- Sperling, MD, D. "Revisions of the Gleason grading system make it more accurate". Sperling Prostate Center. Retrieved 31 March 2016.
- Thorson, Phataraporn; Humphrey, Peter A. (2000). "Minimal Adenocarcinoma in Prostate Needle Biopsy Tissue". American Journal of Clinical Pathology. 114 (6): 896–909. doi:10.1309/KVPX-C1EM-142L-1M6W. PMID 11338479. Pathology slides and explanation. [Free]
- WHO, Geneva Foundation for Medical Education and Research, Prostate cancer, Gleason score. 51 images.